Kazia Therapeutics Ltd
ASX:KZA
Intrinsic Value
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. [ Read More ]
The intrinsic value of one
KZA
stock under the Base Case scenario is
0.002
AUD.
Compared to the current market price of 0.08 AUD,
Kazia Therapeutics Ltd
is
Overvalued by 97%.
Kazia Therapeutics Ltd's market capitalization is 18.2m AUD.
KZA stock price is 0.08 AUD.
KZA stock (0.002 AUD) is 97% less than its price (0.08 AUD).
KZA. Open DCF Valuation
KZA stock (0.002 AUD) is 97% less than its price (0.08 AUD). Open Relative Valuation
KZA has upside potential of 275% compared to the average analyst price target.
Open Wall St Estimates
KZA's short-term assets (11m AUD) exceed its short-term liabilties (8m AUD).
KZA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -86% to -97%, and is approaching profitability.
KZA's long-term assets (28m AUD) exceed its long-term liabilties (16m AUD).
KZA's Revenue has grown by an exceptional 979% over the past 12 months.
KZA's ROE (Return on Equity) has significantly decreased in the last 3 years from -59% to -135%, and is approaching profitability.
KZA has negative Operating Income for the last twelve months.
KZA has negative Net Income for the last twelve months.
KZA's ROE (Return on Equity) for the past 12 months is negative and is equal to -135%.
KZA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -97%.
KZA has negative Net Debt. This means that the company has more cash and short-term investments (5m AUD) than debt (2m AUD).
KZA has negative Free Cash Flow for the last twelve months.
KZA's Revenue has been falling by 30% per year for the last 3 years.
KZA's D/E (Debt to Equity) is very low and is equal to 0.15.
KZA has negative three-year average ROE (Return on Equity): -85%. The company is not efficient at transforming stockholders' equity into net income.
KZA has negative three-year average ROIC (Return on Invested Capital): -81%. The company is not efficient at using invested capital to generate operating income.
KZA's Altman Z-Score is very low and is equal to -5.7.
Valuation Backtest
Kazia Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling
KZA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Kazia Therapeutics Ltd
Balance Sheet Decomposition
Kazia Therapeutics Ltd
| Current Assets | 10.8m |
| Cash & Short-Term Investments | 5.2m |
| Receivables | 3.9m |
| Other Current Assets | 1.6m |
| Non-Current Assets | 17.3m |
| Intangibles | 17.3m |
| Other Non-Current Assets | 42.9k |
| Current Liabilities | 7.6m |
| Accounts Payable | 857.3k |
| Accrued Liabilities | 3.5m |
| Short-Term Debt | 1.8m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 8.5m |
| Other Non-Current Liabilities | 8.5m |
Earnings Waterfall
Kazia Therapeutics Ltd
|
Revenue
|
22.6k
AUD
|
|
Operating Expenses
|
-24.1m
AUD
|
|
Operating Income
|
-24.1m
AUD
|
|
Other Expenses
|
3.7m
AUD
|
|
Net Income
|
-20.5m
AUD
|
Free Cash Flow Analysis
Kazia Therapeutics Ltd
What is Free Cash Flow?
KZA Profitability Score
Profitability Due Diligence
Kazia Therapeutics Ltd's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Kazia Therapeutics Ltd's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
KZA Solvency Score
Solvency Due Diligence
Kazia Therapeutics Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Kazia Therapeutics Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KZA Price Targets Summary
Kazia Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for
KZA
is 0.3 AUD
.
Shareholder Return
KZA Price
Kazia Therapeutics Ltd
| Average Annual Return | 45.37% |
| Standard Deviation of Annual Returns | 50.72% |
| Max Drawdown | -97% |
| Market Capitalization | 18.2m AUD |
| Shares Outstanding | 222 907 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Kazia Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.
Contact
IPO
Employees
Officers
The intrinsic value of one
KZA
stock under the Base Case scenario is
0.002
AUD.
Compared to the current market price of 0.08 AUD,
Kazia Therapeutics Ltd
is
Overvalued by 97%.
You don't have any saved screeners yet
